RNA Therapeutics for Ageing Biology
Key Takeaways
- RNA therapeutics can reduce, replace, redirect, or edit RNA, allowing researchers to test age-associated pathways without permanently changing genomic DNA. [1] [2]
- Ageing-focused evidence includes antisense, messenger-RNA, and microRNA experiments in cultured cells and animal models, but these modalities have not been shown to slow normal human ageing. [1] [4] [5] [6]
- A molecular change such as lower target RNA, altered splicing, or a shifted biomarker is not by itself evidence of improved healthspan or lifespan. [1] [4]
- Cell-specific delivery, durability, innate immune activation, unintended targets, and effects that vary with tissue and age remain major translational constraints. [3] [9]
What Counts as an RNA Therapeutic?
RNA therapeutics are a family of technologies rather than one treatment. Some introduce messenger RNA so that cells temporarily produce a protein. Others bind an existing RNA to promote its degradation, block its translation, or change how a precursor RNA is spliced. MicroRNA mimics and inhibitors alter regulatory networks, while RNA-targeting CRISPR systems can be programmed to modify or degrade selected transcripts. [1] [2]
These approaches act upstream of proteins but downstream of DNA. Their effects can therefore be transient and, in principle, more adjustable than a permanent DNA edit. This does not make them automatically reversible or low risk: the duration depends on chemistry, delivery vehicle, target-cell turnover, and whether the RNA initiates a lasting biological response. [2] [3]
Why RNA Is Studied in Ageing Biology
Ageing is accompanied by changes in gene expression, RNA processing, cellular senescence, immune function, and the regulation of transposable elements. RNA tools are useful because a candidate transcript can be increased or suppressed without first having to develop a small molecule that binds its protein product. This makes RNA therapeutics both experimental probes of causality and possible treatment platforms. [1] [10]
Target selection is unusually difficult in this setting. An age-associated RNA may drive dysfunction, compensate for another change, mark a particular cell population, or have different roles across tissues. Sequence specificity can identify a transcript precisely, but it cannot establish whether changing that transcript will improve organism-level function. [1] [10]
Principal Modalities
| Modality | Intended Action | Ageing-Relevant Use and Limit |
|---|---|---|
| Antisense oligonucleotide (ASO) | A short, single-stranded oligonucleotide binds a chosen RNA and can recruit RNase H, block translation, or redirect splicing. [2] | ASOs can test whether an accumulated or mis-spliced RNA contributes to dysfunction; distribution and chemistry-dependent toxicities constrain interpretation. [3] [4] |
| Small interfering RNA (siRNA) | A double-stranded RNA supplies a guide to the RNA-induced silencing complex, which cleaves complementary messenger RNA. [2] | Silencing can reduce a selected inflammatory or disease-associated protein, but efficient systemic delivery remains concentrated in a limited set of tissues, especially liver. [2] [3] |
| Messenger RNA (mRNA) | Delivered mRNA is translated to supply a protein for a limited period without integrating into the genome. [2] | mRNA can transiently replace a reduced protein or express an enzyme, but protein dose, tissue distribution, and immune sensing require control. [3] [5] |
| MicroRNA modulation | A mimic restores a microRNA signal, whereas an inhibitor reduces the activity of an endogenous microRNA. One microRNA can regulate many transcripts. [1] [9] | Network-level action may alter several age-associated pathways at once, but it also makes mechanism, dose, and unintended effects harder to delimit. [6] [9] |
| RNA editing | Programmable systems recruit an RNA-editing enzyme or an RNA-targeting CRISPR protein to a selected transcript. [1] [8] | Editing avoids an intentional DNA change, but delivery of the editor and guide, transcript selectivity, and immune responses remain unresolved for broad ageing applications. [3] [8] |
What Ageing-Focused Experiments Show
In cells from people with progeroid syndromes, LINE-1 RNA accumulated and interfered with a heterochromatin-regulating enzyme. ASOs directed against LINE-1 RNA restored selected chromatin marks and reduced senescence-associated gene expression. In a Hutchinson–Gilford progeria mouse model, the intervention also improved measured phenotypes and increased lifespan. This is evidence for a defined RNA target in premature-ageing models, not evidence that the same intervention slows usual human ageing. [4]
A different cell study transiently introduced human telomerase reverse transcriptase mRNA into fibroblasts from people with Hutchinson–Gilford progeria syndrome. The treatment lengthened telomeres and improved several cellular measures, including proliferative capacity and some senescence markers. The experiment did not test delivery to tissues, clinical outcomes, or normal ageing in humans. [5]
In aged mice, extracellular vesicles containing microRNA-302b reduced the proliferative arrest of senescent cells by regulating cell-cycle inhibitors. Treated animals showed improvements in several functional measures and lifespan in the reported experimental setting. Because a microRNA has multiple targets and the work used a mouse model, replication, tissue-specific mechanism, dose control, and human safety remain open questions. [6]
Human T-cell studies illustrate a narrower form of evidence. Expression of microRNA-181a declines in naïve CD4 T cells with age and contributes to altered T-cell receptor signalling. This identifies a plausible immune-ageing mechanism, but identifying an age-linked regulatory RNA is not the same as demonstrating a deliverable therapy or improved immune outcomes in older people. [7]
Age-Related Disease Is Not the Same as Ageing
RNA platforms are also being developed for conditions whose incidence rises with age. For example, an RNA-targeting CRISPR–Cas13d system reduced mutant huntingtin RNA and improved selected phenotypes in cellular and mouse models of Huntington's disease. Such work demonstrates programmable transcript targeting in a defined disease model; it does not show that the platform modifies the multi-system biology of ageing. [8]
The distinction matters because treating one pathogenic transcript can be a well-specified goal, whereas ageing involves interacting processes across many cell types. Success against an age-related disease may improve health in later life without changing the rate of ageing, and a change in an ageing-associated molecular marker may occur without clinical benefit. [1] [10]
Delivery and Safety Constraints
Therapeutic RNA must remain intact outside cells, reach the intended tissue, enter the correct cell type, escape intracellular compartments, and engage its target. Chemical modifications, ligand conjugates, lipid nanoparticles, polymers, and extracellular vesicles address different parts of this sequence, but no delivery system distributes every RNA cargo selectively throughout the body. [2] [3]
Ageing adds biological heterogeneity to this engineering problem. Tissue composition, immune state, clearance, and the abundance of a target can differ across individuals and organs, so exposure and effect observed in one model may not transfer directly to another. Repeated dosing may be needed for a transient payload, while a long pharmacological effect can make an unintended response harder to stop. [1] [3]
Safety assessment must include sequence-dependent off-target binding, effects of the chemical backbone or carrier, innate immune activation, organ accumulation, and excessive suppression or expression of the intended target. MicroRNA modulation requires particular caution because one microRNA can regulate many messenger RNAs, making both benefit and harm potentially network-wide. [2] [3] [9]
Evidence Quality and Interpretation
Confidence is high that RNA medicines can alter gene expression in humans for particular diseases; approved ASO and siRNA medicines establish that the platform is clinically viable. That platform-level success does not validate any proposed ageing target, cargo, dose, or delivery route. Each application requires its own evidence for target engagement, functional benefit, and safety. [2] [3]
Confidence is substantially lower for modifying normal human ageing. The strongest ageing-directed examples are preclinical and differ in species, payload, target, delivery system, and outcome. Useful studies should therefore separate molecular effects from tissue function, disease outcomes, healthspan, and lifespan rather than treating them as equivalent endpoints. [1] [4] [5] [6]
Summary
RNA therapeutics provide several ways to interrogate and alter age-associated biology: suppressing a transcript, redirecting splicing, supplying transient protein instructions, modulating regulatory RNAs, or editing RNA directly. Experiments in progeroid cells, mouse models, and age-affected immune cells show biologically meaningful target effects, but they do not establish a therapy for normal human ageing. Translation depends on causal target selection, cell-specific delivery, clinically meaningful endpoints, and long-term safety. [1] [3]
References
- Chen, S. et al. "Using RNA therapeutics to promote healthy aging." Nature Aging (2025). https://doi.org/10.1038/s43587-025-00895-1
- Kulkarni, J. A. et al. "The current landscape of nucleic acid therapeutics." Nature Nanotechnology (2021). https://doi.org/10.1038/s41565-021-00898-0
- Paunovska, K., Loughrey, D. & Dahlman, J. E. "Drug delivery systems for RNA therapeutics." Nature Reviews Genetics (2022). https://doi.org/10.1038/s41576-021-00439-4
- Della Valle, F. et al. "LINE-1 RNA causes heterochromatin erosion and is a target for amelioration of senescent phenotypes in progeroid syndromes." Science Translational Medicine (2022). https://doi.org/10.1126/scitranslmed.abl6057
- Li, Y. et al. "Transient introduction of human telomerase mRNA improves hallmarks of progeria cells." Aging Cell (2019). https://doi.org/10.1111/acel.12979
- Bi, Y. et al. "Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells." Cell Metabolism (2025). https://doi.org/10.1016/j.cmet.2024.11.013
- Ye, Z. et al. "Regulation of miR-181a expression in T cell aging." Nature Communications (2018). https://doi.org/10.1038/s41467-018-05552-3
- Morelli, K. H. et al. "An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington's disease models." Nature Neuroscience (2023). https://doi.org/10.1038/s41593-022-01207-1
- Winkle, M. et al. "Noncoding RNA therapeutics — challenges and potential solutions." Nature Reviews Drug Discovery (2021). https://doi.org/10.1038/s41573-021-00219-z
- López-Otín, C. et al. "Hallmarks of Aging: An Expanding Universe." Cell (2023). https://doi.org/10.1016/j.cell.2022.11.001
This content is provided for academic reference only and does not constitute medical advice. RNA therapeutics intended to modify ageing biology remain experimental, and findings from cells, animals, progeroid syndromes, or individual age-related diseases should not be interpreted as evidence of an approved intervention for normal human ageing.